Novartis AG ADR (NVS)vsStryker Corporation (SYK)
NVS
Novartis AG ADR
$156.33
+1.37%
HEALTHCARE · Cap: $291.32B
SYK
Stryker Corporation
$339.03
+0.47%
HEALTHCARE · Cap: $128.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 119% more annual revenue ($56.69B vs $25.84B). NVS leads profitability with a 22.5% profit margin vs 14.4%. SYK appears more attractively valued with a PEG of 1.55. SYK earns a higher WallStSmart Score of 63/100 (C+).
NVS
Buy51
out of 100
Grade: C-
SYK
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$156.33
$63.60 premium
Margin of Safety
-47.2%
Fair Value
$228.91
Current Price
$339.03
$110.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 27.0%
Earnings expanding 44.1% YoY
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
SYK carries more volatility with a beta of 0.77 — expect wider price swings.
SYK is growing revenue faster at 9.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (63/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?